NASDAQ
2.87USD
-0.04 (-1.21%)
We have scored 11 news catalysts on PepGen Inc. (PEPG) over the past 12 months. The biggest single-day move next to one of them came Sep 19, 2025, when PEPG closed −8.3%: “Kuehn Law Encourages Investors of PepGen Inc. to Contact Law Firm”. Coverage across the window leans negative (average ticker sentiment −0.51). Most of the impact sits in price momentum and institutional appeal.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
201.6M
P/E
—
EPS
—
Beta
1.97
52W range
1.31-7.8
Day range
2.85–2.94
Open
2.90
Prev close
2.90
Volume
100.7K
Avg volume
873.8K
Dividend
0.00
IPO
2022-05-06
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about PepGen Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for PEPG: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
